Drug Profile

LX 1001

Alternative Names: AAVrh.10hAPOE2; LX-1001

Latest Information Update: 19 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Weill Cornell Medicine
Developer LEXEO Therapeutics; Weill Cornell Medicine
Class Antidementias; Gene therapies; Neuroprotectants
Mechanism of Action Apolipoprotein E2 expression stimulants; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Alzheimer's disease

Most Recent Events

13 Nov 2024 Updated adverse events data from a phase-I/II trial in Alzheimer’s disease released by Lexeo Therapeutics
07 Nov 2024 Lexeo Therapeutics completes a phase I/II LEAD trial in Alzheimer's disease in USA (NCT03634007)
30 Oct 2024 Pharmacodynamics and adverse events data from a phase-I/II trial in Alzheimer’s disease released by Lexeo Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com